beta blocker: be contraindicated in cardiogenic shock

from Quasimodo
0.2 0.4 0.6 0.8 Plausible Typical Remarkable Salient

Related concepts

Parents agent
Weight: 0.65
, high blood pressure
Weight: 0.63
, heart disease
Weight: 0.63
, vasodilator
Weight: 0.62
Siblings atenolol
Weight: 0.53
, lung cancer
Weight: 0.33
, cystic fibrosis
Weight: 0.33
, agonist
Weight: 0.32
, blood clot
Weight: 0.32

Related properties

Property Similarity
be contraindicated in cardiogenic shock 1.00
be contraindicated in shock 0.97
be contraindicated in myasthenia gravis 0.94
be contraindicated in in raynaud 0.93
be contraindicated in pheochromocytoma 0.93
be contraindicated in copd 0.92
be contraindicated in decompensated heart failure 0.91
be contraindicated in disease 0.91
be contraindicated in heart failure 0.91
be contraindicated in patients 0.91

Priors about this statement

Cues

0.2 0.4 0.6 0.8 Joint Necessity Sufficiency Implication Entailment Contradiction Entropy

Evidence

0.2 0.4 0.6 0.8 Plausible Typical Remarkable Salient

Clauses

Remarkability exclusitivity between siblings

0.07
Rule weight: 0.13
Evidence weight: 0.59
Similarity weight: 0.91
Evidence: 0.79
¬ Remarkable(beta blocker, be contraindicated in cardiogenic shock) ⋁
Evidence: 0.52
¬ Remarkable(atenolol, be contraindicated in heart failure)

Remarkability from sibling implausibility

0.47
Rule weight: 0.60
Evidence weight: 0.85
Similarity weight: 0.91
Evidence: 0.60
Plausible(beta blocker, be contraindicated in cardiogenic shock) ⋁
Evidence: 0.52
Remarkable(atenolol, be contraindicated in heart failure) ⋁
Evidence: 0.79
¬ Plausible(atenolol, be contraindicated in heart failure)

Salient implies Plausible

0.20
Rule weight: 0.28
Evidence weight: 0.70
Similarity weight: 1.00
Evidence: 0.60
Plausible(beta blocker, be contraindicated in cardiogenic shock) ⋁
Evidence: 0.77
¬ Salient(beta blocker, be contraindicated in cardiogenic shock)

Similarity expansion

0.69
Rule weight: 0.85
Evidence weight: 0.88
Similarity weight: 0.93
Evidence: 0.79
Remarkable(beta blocker, be contraindicated in cardiogenic shock) ⋁
Evidence: 0.58
¬ Remarkable(beta blocker, be contraindicated in pheochromocytoma)
0.67
Rule weight: 0.85
Evidence weight: 0.85
Similarity weight: 0.93
Evidence: 0.77
Salient(beta blocker, be contraindicated in cardiogenic shock) ⋁
Evidence: 0.66
¬ Salient(beta blocker, be contraindicated in in raynaud)
0.67
Rule weight: 0.85
Evidence weight: 0.85
Similarity weight: 0.92
Evidence: 0.77
Salient(beta blocker, be contraindicated in cardiogenic shock) ⋁
Evidence: 0.66
¬ Salient(beta blocker, be contraindicated in copd)
0.67
Rule weight: 0.85
Evidence weight: 0.85
Similarity weight: 0.92
Evidence: 0.79
Remarkable(beta blocker, be contraindicated in cardiogenic shock) ⋁
Evidence: 0.74
¬ Remarkable(beta blocker, be contraindicated in copd)
0.67
Rule weight: 0.85
Evidence weight: 0.86
Similarity weight: 0.91
Evidence: 0.79
Remarkable(beta blocker, be contraindicated in cardiogenic shock) ⋁
Evidence: 0.68
¬ Remarkable(beta blocker, be contraindicated in heart failure)
0.66
Rule weight: 0.85
Evidence weight: 0.83
Similarity weight: 0.94
Evidence: 0.77
Salient(beta blocker, be contraindicated in cardiogenic shock) ⋁
Evidence: 0.72
¬ Salient(beta blocker, be contraindicated in myasthenia gravis)
0.66
Rule weight: 0.85
Evidence weight: 0.84
Similarity weight: 0.93
Evidence: 0.79
Remarkable(beta blocker, be contraindicated in cardiogenic shock) ⋁
Evidence: 0.79
¬ Remarkable(beta blocker, be contraindicated in in raynaud)
0.66
Rule weight: 0.85
Evidence weight: 0.85
Similarity weight: 0.91
Evidence: 0.79
Remarkable(beta blocker, be contraindicated in cardiogenic shock) ⋁
Evidence: 0.74
¬ Remarkable(beta blocker, be contraindicated in decompensated heart failure)
0.66
Rule weight: 0.85
Evidence weight: 0.83
Similarity weight: 0.94
Evidence: 0.56
Typical(beta blocker, be contraindicated in cardiogenic shock) ⋁
Evidence: 0.40
¬ Typical(beta blocker, be contraindicated in myasthenia gravis)
0.66
Rule weight: 0.85
Evidence weight: 0.82
Similarity weight: 0.94
Evidence: 0.79
Remarkable(beta blocker, be contraindicated in cardiogenic shock) ⋁
Evidence: 0.86
¬ Remarkable(beta blocker, be contraindicated in myasthenia gravis)
0.64
Rule weight: 0.85
Evidence weight: 0.80
Similarity weight: 0.94
Evidence: 0.60
Plausible(beta blocker, be contraindicated in cardiogenic shock) ⋁
Evidence: 0.51
¬ Plausible(beta blocker, be contraindicated in myasthenia gravis)
0.64
Rule weight: 0.85
Evidence weight: 0.80
Similarity weight: 0.93
Evidence: 0.56
Typical(beta blocker, be contraindicated in cardiogenic shock) ⋁
Evidence: 0.44
¬ Typical(beta blocker, be contraindicated in in raynaud)
0.64
Rule weight: 0.85
Evidence weight: 0.81
Similarity weight: 0.91
Evidence: 0.77
Salient(beta blocker, be contraindicated in cardiogenic shock) ⋁
Evidence: 0.79
¬ Salient(beta blocker, be contraindicated in decompensated heart failure)
0.63
Rule weight: 0.85
Evidence weight: 0.80
Similarity weight: 0.93
Evidence: 0.77
Salient(beta blocker, be contraindicated in cardiogenic shock) ⋁
Evidence: 0.84
¬ Salient(beta blocker, be contraindicated in pheochromocytoma)
0.63
Rule weight: 0.85
Evidence weight: 0.80
Similarity weight: 0.93
Evidence: 0.60
Plausible(beta blocker, be contraindicated in cardiogenic shock) ⋁
Evidence: 0.50
¬ Plausible(beta blocker, be contraindicated in in raynaud)
0.63
Rule weight: 0.85
Evidence weight: 0.79
Similarity weight: 0.92
Evidence: 0.60
Plausible(beta blocker, be contraindicated in cardiogenic shock) ⋁
Evidence: 0.53
¬ Plausible(beta blocker, be contraindicated in copd)
0.62
Rule weight: 0.85
Evidence weight: 0.80
Similarity weight: 0.91
Evidence: 0.77
Salient(beta blocker, be contraindicated in cardiogenic shock) ⋁
Evidence: 0.86
¬ Salient(beta blocker, be contraindicated in heart failure)
0.62
Rule weight: 0.85
Evidence weight: 0.78
Similarity weight: 0.92
Evidence: 0.56
Typical(beta blocker, be contraindicated in cardiogenic shock) ⋁
Evidence: 0.50
¬ Typical(beta blocker, be contraindicated in copd)
0.57
Rule weight: 0.85
Evidence weight: 0.74
Similarity weight: 0.91
Evidence: 0.60
Plausible(beta blocker, be contraindicated in cardiogenic shock) ⋁
Evidence: 0.67
¬ Plausible(beta blocker, be contraindicated in decompensated heart failure)
0.55
Rule weight: 0.85
Evidence weight: 0.71
Similarity weight: 0.91
Evidence: 0.56
Typical(beta blocker, be contraindicated in cardiogenic shock) ⋁
Evidence: 0.66
¬ Typical(beta blocker, be contraindicated in decompensated heart failure)
0.54
Rule weight: 0.85
Evidence weight: 0.69
Similarity weight: 0.93
Evidence: 0.60
Plausible(beta blocker, be contraindicated in cardiogenic shock) ⋁
Evidence: 0.79
¬ Plausible(beta blocker, be contraindicated in pheochromocytoma)
0.54
Rule weight: 0.85
Evidence weight: 0.70
Similarity weight: 0.91
Evidence: 0.60
Plausible(beta blocker, be contraindicated in cardiogenic shock) ⋁
Evidence: 0.76
¬ Plausible(beta blocker, be contraindicated in heart failure)
0.51
Rule weight: 0.85
Evidence weight: 0.65
Similarity weight: 0.91
Evidence: 0.56
Typical(beta blocker, be contraindicated in cardiogenic shock) ⋁
Evidence: 0.79
¬ Typical(beta blocker, be contraindicated in heart failure)
0.50
Rule weight: 0.85
Evidence weight: 0.63
Similarity weight: 0.93
Evidence: 0.56
Typical(beta blocker, be contraindicated in cardiogenic shock) ⋁
Evidence: 0.85
¬ Typical(beta blocker, be contraindicated in pheochromocytoma)

Typical and Remarkable implies Salient

0.12
Rule weight: 0.14
Evidence weight: 0.90
Similarity weight: 1.00
Evidence: 0.77
Salient(beta blocker, be contraindicated in cardiogenic shock) ⋁
Evidence: 0.56
¬ Typical(beta blocker, be contraindicated in cardiogenic shock) ⋁
Evidence: 0.79
¬ Remarkable(beta blocker, be contraindicated in cardiogenic shock)

Typical implies Plausible

0.37
Rule weight: 0.48
Evidence weight: 0.78
Similarity weight: 1.00
Evidence: 0.60
Plausible(beta blocker, be contraindicated in cardiogenic shock) ⋁
Evidence: 0.56
¬ Typical(beta blocker, be contraindicated in cardiogenic shock)

Typicality and Rermarkability incompatibility between siblings

0.04
Rule weight: 0.14
Evidence weight: 0.32
Similarity weight: 0.91
Evidence: 0.79
¬ Remarkable(beta blocker, be contraindicated in cardiogenic shock) ⋁
Evidence: 0.86
¬ Typical(atenolol, be contraindicated in heart failure)